Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2005

View Archived Issues

New and potent non-nucleoside inhibitors of wild-type and mutant reverse transcriptases

Tripep reports on ChronVac developments

Phase II study assesses 17-AAG for Von Hippel-Lindau disease

Aplidin enters phase II for prostate and bladder cancers

Preclinical results from EntreMed's PAR-2 inhibitor program

Memory adds PDE10A inhibitor program to pipeline

Enrollment completed in phase II colorectal cancer study of HGS-ETR1

Kaken launches GHRP Kaken 100 in Japan

Sosei inlicenses urology drug from Otsuka

Triple inhibitors tested for the treatment of cardiovascular and renal diseases / News in Context

Millenia Hope studies MMH-8 Malarex in new pediatric study

New indication approved for pazufloxacin mesilate in Japan

Transgene has new strategy in therapeutic vaccines

Kissei presents new beta3-adrenoceptor agonists

Sodium-glucose cotransporter inhibitors jointly reported by Yamanouchi and Kotobuki

Novel antifungal agents discovered by SSP

European approval for Truvada

Roche discloses new mGluR5 receptor antagonists for anxiety and pain

Fuji Photo Film announces pyranose derivatives for use in X-ray contrast media

Pegasys approved for hepatitis B in Europe

Novel Raf kinase inhibitors claimed by Novartis for the treatment of cancer

Daiichi Pharmaceutical and Sankyo to integrate businesses

Pfizer discloses cannabinoid CB1 receptor antagonists for treating obesity and alcohol dependence

Clinical trials evaluate the antiviral effects and safety of PA-457 in HIV infection

Promising effects found with an amdoxovir/enfuvirtide regimen in HIV infection

Good safety profile reported for 640385 in healthy volunteers

Add-on capravirine enhances the efficacy of a standard-of-care antiretroviral regimen

Phase I data on the toxicity of BAY-43-9006 in patients with advanced solid tumors

Cizolirtine enters phase II for stress urinary incontinence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...